The Journal. Inside the Crisis at Tylenol
132 snips
Sep 30, 2025 
In this discussion, Wall Street Journal reporter Peter Loftus provides insight into the crisis surrounding Tylenol, sparked by Donald Trump's controversial claims linking acetaminophen to autism. Loftus elaborates on Kenvue CEO Kirk Perry's swift response to the uproar and the pressure he faced. They delve into the nuances of the research on acetaminophen and autism, contrasting it with past PR crises, and explore the wider implications for pharma companies under a politicized administration. This riveting conversation offers a deep dive into crisis management in the modern age.
AI Snips
Chapters
Transcript
Episode notes
Interim CEO Came Out Of Retirement
- Kirk Perry unretired after being asked to be interim CEO to turn around Kenview.
- He left retirement plans like elk hunting to take on the company's leadership during a difficult period.
Tylenol Still Powers Sales
- Tylenol remains a strong brand despite cheap generics and makes about 10% of Kenview's sales.
- That share makes Tylenol a strategically important product to sustain the newly independent company.
Meeting With RFK Jr. Felt Cordial
- Kenview executives, including Kirk Perry, met RFK Jr. and argued studies were inconclusive and alternatives in pregnancy are limited.
- RFK asked for more meetings and research, leaving Kenview cautiously optimistic after a cordial session.